BMC Oral Health· 2026Q1
Evaluation of serum and salivary interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF- α) biomarkers in patients with temporomandibular disorders
- 0citations
- Q1SCImago
- 2026year
Short summary
Salivary IL-1β levels are significantly higher in Nigerian patients with temporomandibular disorders (TMD) compared to healthy controls (median 963.5 pg/ml vs. 560.6 pg/ml, p <0.001).
AI-generated from the title and abstract; the full text is not read.
Key points
- Salivary IL-1β levels were significantly higher in TMD patients (median 963.5 pg/ml) than in controls (median 560.6 pg/ml) (p <0.001).
- No significant difference was found in salivary TNF-α levels between TMD patients and controls (p = 0.154).
- The study measured IL-1β and TNF-α in serum and saliva from 50 Nigerian participants (25 TMD patients, 25 controls).
- Salivary IL-1β may serve as a reliable biomarker for evaluating TMD treatment effectiveness.
AI-generated from the title and abstract; the full text is not read.
Abstract
Biomarkers like TNF-α and IL-1 are increasingly recognised as promising tools for enhancing TMD diagnosis and treatment. These biomarkers are detectable in synovial fluid, saliva, and blood. Salivary and serum biomarkers are increasingly favoured over synovial fluid biomarkers because they are easier to access. Despite this, no study has assessed the levels of these biomarkers in Nigerian patients with TMD. Therefore, this study aimed to evaluate salivary and serum levels of IL-1β and TNF- α in Nigerian patients with TMDs. Methods This 12-month study included 50 participants aged 18 years and above, who were assessed using the Diagnostic Criteria for TMDs and assigned in equal numbers of 25 to either the case group (patients with TMD) or the control group. Venous blood (5mls) and 5mls of unstimulated whole saliva were collected from each participant. The samples were assayed for the biomarkers using the Enzyme-linked Immunosorbent assay (ELISA) method. Data were analysed using SPSS version 26 with significance set at p <0.05. Results The salivary levels of IL-1β in the case group ranged from 317.3-1231.0pg/ml, with the median value of 963.5(265.0)pg/ml, while those of the control group ranged from 12.2-1187.0pg/ml, with a median value of 560.6(491.80)pg/ml. The level of IL-1β in the saliva of the case group was significantly higher than that of the control group ( p <0.001). The salivary levels of TNF- α in the case group ranged from 120.1-891.7pg/ml with a median value of 616.9(194.7)pg/ml, while those of the control group ranged from 105.8-810.2pg/ml with the median being 524.7(283.3)pg/ml. There was no statistically significant difference in the groups ( p = 0.154). Conclusion The TMD patients have a significantly higher level of salivary IL-1β than the normal individuals. Hence, it may be a more reliable biomarker for assessing the effectiveness of therapeutic intervention in TMDs.
The authors' abstract, as published at the source. BMC Oral Health, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Complementary and Manual Therapy
Complementary and Manual TherapyHealth Professions